首页
>
期刊首页
>
药学学报(英文版)
>
2026年5期
>
Targeting cancer-associated fibroblast-activated HGF/c-MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity
Targeting cancer-associated fibroblast-activated HGF/c-MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity
摘要
Cholangiocarcinoma(CCA)is a markedly desmoplastic tumor,with extrahepatic CCA(eCCA)being the most prevalent subtype.The nonspecific clinical manifestation and early metastatic potential result in a persistently poor overall prognosis.Cancer-associated fibroblasts(CAFs)are one of the major components of the tumor microenvironment implicated in tumor progression and treatment resistance.To faithfully recapit-ulate the eCCA microenvironment,we established a comprehensive patient-derived preclinical platform comprising CAFs,eCCA primary cells,organoids,and patient-derived xenograft(PDX)models.We found that CAFs facilitated eCCA cell growth,migration,and invasion in vivo and in vitro.Cytokine profiling revealed that HGF is a key paracrine factor produced by CAFs.CAF-derived HGF activates c-MET signaling to drive gemcitabine resistance in eCCA.Therapeutically,pharmacologic inhibition of c-MET partially resensitized eCCA cells to gemcitabine in preclinical models and suppressed tumor progression.In conclusion,our data provides subtype-specific translational evidence that therapeutically targeting the CAF-HGF-c-MET pathway represents a rational strategy to enhance gemcitabine efficacy and improve treatment outcomes in eCCA.
年,卷(期):
2026, 16(5)
机标分类号:
R735.9
R6
R979.1
在线出版日期:
2026年7月1日